



Press release

New technology for biomarker validation

823 characters.

Contact: Markus Fischer. info@polyquant.com

This press release is also available in electronic form at www.polyquant.com/presse.

Regensburg, 01. April 2008 – The Regensburg-based startup PolyQuant presents a new technology at Analytica which significantly facilitates the validation of biomarkers. With the increasing specificity of newly developed drugs, the demand for an efficient identification of target patient groups increases as well. This demand can be met by biomarkers that provide insight into physiological states of patients and into the effects of drugs on the patients' physiology.

With QconCAT, PolyQuant provides a standard for the quantification of a broad panel of up to 100 biomarkers in a single multiplex analysis. QconCAT is a polypeptide of proteotypic peptides that serve as internal standard for protein quantification. QconCAT enables researchers to test large sets of proteins for their applicability as specific biomarkers.

About PolyQuant GmbH

PolyQuant GmbH has been founded in 2007, with the aim to provide targeted solutions for quantitative proteomics, protein analysis and protein expression. The main field of business is the proteome analysis, using the QconCAT method. The development of QconCAT has been funded by the BioChancePlus program. PolyQuant is a spin-off of Entelechon GmbH, a company who has been on the market of gene synthesis and bioinformatics since 1999.

Contact

PolyQuant GmbH
St. Veit-Weg 2
93051 Regensburg
Germany
Tel. +49 941.9468.360
Fax +49 941.9468.366
info@polyquant.com
www.polyquant.com